Sugi Predict

Sugi Predict / Compounds / SCHEMBL20557993

SCHEMBL20557993

SCHEMBL20557993

Fc1cncc(-c2cc(NCCc3c[nH]c4ccccc34)n3ncc(C4CCCO4)c3n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ EIF2AK2 P19525 2/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ MAPT P10636 3/20 0.37
▸ GBA1 P04062 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ GPR18 Q14330 3/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HRH3 Q9Y5N1 3/20 0.36
▸ ADK P55263 1/20 0.36
▸ HTR6 P50406 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ SLC2A1 P11166 1/20 0.35
▸ RAD52 P43351 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21754191 0.90 KMT2A (0.40) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL31747036 0.83 KMT2A (0.43) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL29727526 0.83 KMT2A (0.43) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL21754124 0.83 CDK2 (0.46) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL20557535 0.83 KMT2A (0.43) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL20557999 0.83 KMT2A (0.43) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL20542149 0.83 KMT2A (0.43) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL30579406 0.83 KMT2A (0.43) LMNAALDH1A1EIF2AK2KMT2AMEN1
SCHEMBL20557670 0.82 GSK3B (0.46) ALDH1A1EIF2AK2KMT2AMEN1GBA1
SCHEMBL20542242 0.82 SYK (0.42) LMNAALDH1A1EIF2AK2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 LMNA 4480/4885ALDH1A1 316/4885EIF2AK2 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback